Calcium study for advanced neuroendocrine tumours
Part of Cancer clinical trials.
This trial tests a new calcium-based medicine (AUR103) for people with neuroendocrine tumours that have spread and are no longer responding to standard treatments. It aims to see if this medicine can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your tumour must be a slow-growing (grade 1 or 2) neuroendocrine tumour that is advanced and cannot be removed by surgery.
- You must have already tried at least one approved treatment for neuroendocrine tumours (like everolimus, sunitinib, cabozantinib, or lutetium-177 dotatate), and your disease must have progressed.
- You must be generally well enough to carry out daily activities (ECOG score 0 or 1).
- You must have measurable disease (tumours that can be seen and measured on scans).
- You must have adequate kidney, liver, and blood function (your doctor will test this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is tracking patients with advanced neuroendocrine tumors to see which treatments help them live longer without severe side effects, and how these side effects affect daily life. It aims to find the best treatment approaches for people like you.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a new combination of drugs as the first treatment for people with advanced neuroendocrine cancer of the digestive system that has spread. It aims to see if the combination can shrink tumors and help people live longer.
This trial tests a new drug called SHR-A1904 for people with advanced neuroendocrine carcinoma that has grown after standard chemotherapy. The drug is given alone and may help shrink tumors or slow the disease.
This study tests an immunotherapy drug (CTX-471) for people with a specific type of advanced neuroendocrine tumor that has grown after chemotherapy. The goal is to see if the drug can help shrink or control the tumor.
Hear when a new Neuroendocrine (NE) Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.